[go: up one dir, main page]

ES2076895B1 - Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones. - Google Patents

Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones.

Info

Publication number
ES2076895B1
ES2076895B1 ES09400202A ES9400202A ES2076895B1 ES 2076895 B1 ES2076895 B1 ES 2076895B1 ES 09400202 A ES09400202 A ES 09400202A ES 9400202 A ES9400202 A ES 9400202A ES 2076895 B1 ES2076895 B1 ES 2076895B1
Authority
ES
Spain
Prior art keywords
type
coli
procedure
fimbries
fimbrias
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09400202A
Other languages
English (en)
Other versions
ES2076895A1 (es
Inventor
Quesada Jorge Martinez
Garate Alberto Martinez
Pelaez Ricardo Palacios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Farmaceutica y de Especialidades SA
Original Assignee
Industrial Farmaceutica y de Especialidades SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Farmaceutica y de Especialidades SA filed Critical Industrial Farmaceutica y de Especialidades SA
Priority to ES09400202A priority Critical patent/ES2076895B1/es
Priority to CA002141475A priority patent/CA2141475C/en
Priority to AU11503/95A priority patent/AU691221B2/en
Priority to DK95200257T priority patent/DK0666271T3/da
Priority to AT95200257T priority patent/ATE185814T1/de
Priority to PT95200257T priority patent/PT666271E/pt
Priority to DE69512808T priority patent/DE69512808T2/de
Priority to EP95200257A priority patent/EP0666271B1/en
Priority to JP7016819A priority patent/JP2851556B2/ja
Priority to BR9500546A priority patent/BR9500546A/pt
Publication of ES2076895A1 publication Critical patent/ES2076895A1/es
Application granted granted Critical
Publication of ES2076895B1 publication Critical patent/ES2076895B1/es
Priority to US09/128,484 priority patent/US6471966B1/en
Priority to GR20000400030T priority patent/GR3032332T3/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Paints Or Removers (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

FIMBRIAS-ADHESINAS DE TIPO 1 Y P AISLADAS DE NUEVAS CEPAS DE E. COSI, PROCEDIMIENTO PARA SU OBTENCION Y APLICACIONES. LAS FIMBRIAS ADHESINAS TIENEN UN PESO MOLECULAR DE 2X105 Y 2X107 DA, Y COMPRENDEN 90-95 POR CIENTO DE PROTEINAS Y 1-3 POR CIENTO DE AZUCARES. LAS FIMBRIAS DE TIPO 1 MUESTRAN 5 FRACCIONES PROTEICAS DIFERENTES DE 14-20 KDA ESTANDO ASOCIADA LA MAYORIA A CARBOHIDRATOS. LAS FIMBRIAS DE TIPO P TAMBIEN INCLUYEN 5 FRACCIONES PROTEICAS DIFERENTES DE 14-20 KDA ESTANDO UNA DE LAS MAYORITARIAS ASOCIADA A CARBOHIDRATOS. EL PROCEDIMIENTO COMPRENDE: CULTIVAR CEPAS DE E. COLI CECT 4484 Y CECT 4485; RECOGER EL SEDIMENTO POR CENTRIFUGACION, RESUSPENDERLO EN SUERO FISIOLOGICO Y HOMOGENEIZAR; CENTRIFUGAR EL HOMOGENEIZADO RECOGIENDO EL SOBRENADANTE, QUE SE SOMETE A PRECIPITACION SALINA, RECONSTITUIR EL PRECIPITADO Y DIALIZAR LA SOLUCION; TRATAR EL DIALIZADO CON DESOXICOLATO SODICO Y, SOMETER EL PRODUCTO A DOS CROMATOGRAFIAS SUCESIVAS CON SEPHACRYL S-200 Y SEPHAROSA 4B. APLICACION EN EL TRATAMIENTO Y PREVENCION DE LAS INFECCIONES DEL TRACTO URINARIO PRODUCIDAS POR E. COLI FIMBRIADAS.
ES09400202A 1994-02-04 1994-02-04 Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones. Expired - Fee Related ES2076895B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES09400202A ES2076895B1 (es) 1994-02-04 1994-02-04 Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones.
CA002141475A CA2141475C (en) 1994-02-04 1995-01-31 Type 1 and type p fimbriae-adhesins isolated from novel e. coli strains, process for their preparation and uses thereof
AU11503/95A AU691221B2 (en) 1994-02-04 1995-02-01 Type 1 and type P fimbriae-adhesins isolated from novel E coli strains, process for their preparation and uses thereof
DE69512808T DE69512808T2 (de) 1994-02-04 1995-02-02 Aus neuen E.Coli Stämmen isolierte Typ 1 und Typ P Fibrillen-Adhesine, Verfahren zu ihrer Herstellung und ihre Verwendungen
AT95200257T ATE185814T1 (de) 1994-02-04 1995-02-02 Aus neuen e.coli stämmen isolierte typ 1 und typ p fibrillen-adhesine, verfahren zu ihrer herstellung und ihre verwendungen
PT95200257T PT666271E (pt) 1994-02-04 1995-02-02 Adesinas de fimbrias de tipo 1 e de tipo p isoladas a partir de novas estirpes de e. coli processo para a sua preparacao e sua utilizacao
DK95200257T DK0666271T3 (da) 1994-02-04 1995-02-02 Type 1- og type P-fimbriae-adhæsioner isoleret fra nye E. coli-stammer, fremgangsmåde til deres fremstilling og deres anven
EP95200257A EP0666271B1 (en) 1994-02-04 1995-02-02 Type 1 and type P fimbriae-adhesins isolated from novel E. coli strains, process for their preparation and uses thereof
JP7016819A JP2851556B2 (ja) 1994-02-04 1995-02-03 新規なエシェリキア・コリ菌株から単離した１型およびｐ型フィムブリエ−アドヘシン、その製法ならびにその使用
BR9500546A BR9500546A (pt) 1994-02-04 1995-02-06 Fimbrias - adesinas e processo para a preparaçao de fimbrias - adesinas
US09/128,484 US6471966B1 (en) 1994-02-04 1998-08-04 Type 1 and type p fimbriae-adhesins isolated from novel e. coli strains, process for their preparation and uses thereof
GR20000400030T GR3032332T3 (en) 1994-02-04 2000-01-12 Type 1 and type P fimbriae-adhesins isolated from novel E. coli strains, process for their preparation and uses thereof.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09400202A ES2076895B1 (es) 1994-02-04 1994-02-04 Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones.

Publications (2)

Publication Number Publication Date
ES2076895A1 ES2076895A1 (es) 1995-11-01
ES2076895B1 true ES2076895B1 (es) 1996-08-16

Family

ID=8285106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09400202A Expired - Fee Related ES2076895B1 (es) 1994-02-04 1994-02-04 Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones.

Country Status (11)

Country Link
EP (1) EP0666271B1 (es)
JP (1) JP2851556B2 (es)
AT (1) ATE185814T1 (es)
AU (1) AU691221B2 (es)
BR (1) BR9500546A (es)
CA (1) CA2141475C (es)
DE (1) DE69512808T2 (es)
DK (1) DK0666271T3 (es)
ES (1) ES2076895B1 (es)
GR (1) GR3032332T3 (es)
PT (1) PT666271E (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402602A1 (en) * 2000-03-10 2001-09-13 Edouard Bingen Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides
EP1342784A1 (en) * 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836349B (en) * 1982-09-02 1985-04-24 Unilever Plc Production of antibodies
DK41885A (da) * 1985-01-31 1986-11-13 Slagteriernes Forskningsinst 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
US4725435A (en) * 1986-06-18 1988-02-16 Bactex, Inc. Vaccine composition for immunization against urinary tract infection caused by E. coli
WO1990000614A1 (en) * 1988-07-13 1990-01-25 Baylor College Of Medicine Receptor specific proteins and their use in receptor typing
DE3832785A1 (de) * 1988-09-27 1990-04-19 Max Planck Gesellschaft Verfahren zur gewinnung von p-adhaesin

Also Published As

Publication number Publication date
ATE185814T1 (de) 1999-11-15
DK0666271T3 (da) 2000-04-17
BR9500546A (pt) 1997-05-27
ES2076895A1 (es) 1995-11-01
CA2141475A1 (en) 1995-08-05
EP0666271A1 (en) 1995-08-09
EP0666271B1 (en) 1999-10-20
AU1150395A (en) 1995-08-17
JPH0834798A (ja) 1996-02-06
CA2141475C (en) 1999-08-24
JP2851556B2 (ja) 1999-01-27
DE69512808D1 (de) 1999-11-25
DE69512808T2 (de) 2000-06-15
PT666271E (pt) 2000-04-28
AU691221B2 (en) 1998-05-14
GR3032332T3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
Yang et al. Preparation and characterization of gelatin and antioxidant peptides from gelatin hydrolysate of skipjack tuna (Katsuwonus pelamis) bone stimulated by in vitro gastrointestinal digestion
Borad et al. Colostrum immunoglobulins: Processing, preservation and application aspects
Tao et al. Bioactive peptides from cartilage protein hydrolysate of spotless smoothhound and their antioxidant activity in vitro
González-Chávez et al. Lactoferrin: structure, function and applications
Akalın Dairy-derived antimicrobial peptides: Action mechanisms, pharmaceutical uses and production proposals
Merchant et al. Antiviral activity of serum from the American alligator (Alligator mississippiensis)
Yim et al. Antiviral effects of sulfated exopolysaccharide from the marine microalga Gyrodinium impudicum strain KG03
Derdak et al. Insights on health and food applications of Equus asinus (donkey) milk bioactive proteins and peptides—an overview
Li et al. Antioxidant activity of coconut (Cocos nucifera L.) protein fractions
Birkemo et al. Antimicrobial activity of two peptides casecidin 15 and 17, found naturally in bovine colostrum
DMSc et al. Physiologic role of the complement system in host defense, disease, and malnutrition
JP2015513904A (ja) 栄養断片、タンパク質、および方法
Xiong et al. A normal mucin-binding lectin from the sponge Craniella australiensis
Nojima et al. Lactoferrin conjugated with 40-kDa branched poly (ethylene glycol) has an improved circulating half-life
Arafa et al. The effectiveness of Echinacea extract or composite glucosamine, chondroitin and methyl sulfonyl methane supplements on acute and chronic rheumatoid arthritis rat model
Une et al. Lectin isolated from Japanese red sword beans (Canavalia gladiata) as a potential cancer chemopreventive agent
Naik et al. Biochemical Characterization of lactose binding Entadin lectin from Entada rheedii seeds with cytotoxic activity against cancer cell lines
ES2076895B1 (es) Fimbrias-adhesinas de tipo 1 y p aisladas de nuevas cepas de e. coli, procedimiento para su obtencion y aplicaciones.
Mpandi et al. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins
US8815812B2 (en) Synthetic arginine substituted peptides and their use
Karthik et al. Structural characterization, teratogenicity and in vitro avian antimicrobial activity of posterior salivary gland (PSG) toxin from cuttlefish, Sepia prashadi
Khwaldia Chondroitin and glucosamine
CN114716538B (zh) 一种人乳铁蛋白突变体及其与双歧杆菌在制备食品或保健品中的应用
Zambrowicz et al. The effect of carbohydrate moieties on immunoregulatory activity of yolkin polypeptides naturally occurring in egg yolk
Wang et al. Effects of interaction on the structure and potential allergenicity of ovalbumin and lysozyme.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19940204

Kind code of ref document: B1

Effective date: 19940204

PC2A Transfer of patent
PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20180806